PTPRC and neoplasm: However, exclusive treatment with IHCH9033 (60 mg/kg, once every 2 days) significantly decreased the proportions of hCD45+ cells and/or hCD34+ CD45+ cells, signifying a reduced tumor burden within the bone marrow (BM), spleen, and peripheral blood (PB) of mice models (Fig. 6b–i).